Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients

Journal of Neuro-Oncology

Volumn 38, Issue 1, 1998, Pages 59-68

  Mastronardi, Luciano ^a,d   Puzzilli, Fabrizio ^b   Couldwell, William T ^c   Farah, Jibril Osman ^b   Lunardi, Pierpaolo ^b  

^a Civilian Hospital of Terni   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d NONE   (Italy)

Author keywords

Carboplatin; Chemotherapy; Malignant glioma; Surgery; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; FEMALE; GLIOBLASTOMA; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MALE; MORTALITY; NAUSEA; ORAL DRUG ADMINISTRATION; POSTOPERATIVE CARE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MALE; MIDDLE AGED; SUPRATENTORIAL NEOPLASMS; TAMOXIFEN;

EID: 0031907929     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005968724240     Document Type: Article

References (57)

1. Schoenberg BS: The epidemiology of central nervous system tumors. In: Walker MD (ed) Oncology of the Nervous System. Martinus Nijhoff 1-30, 1983
2. Couldwell WT, Antel JP, Apuzzo MLJ, Yong VW: Inhibition of growth of established human glioma lines by modulators of the protein kinase-C system. J Neurosurg 73:594-600, 1990
3. Couldwell WT, Hinton DR, He S, Chen T, Sabit I, Weiss MH, Law R: Protein kinase C inhibitors induce apoptosis in human malignant glioma lines. FEBS Lett 345: 43-46, 1994
4. Daumas-Duport C, Scheithauer B, O'Fallon J: Grading of astrocytomas: a simple and reproducible method. Cancer 62: 2152-2165, 1988
5. Feun LG, Stewart DJ, Maor M: A pilot study of cisdiammine-dichloroplatinum and radiation therapy in patients with high grade astrocytomas. J Neuro-Oncol 1: 109-113, 1983
6. Gainon P, Ettinger LJ, Baum E: Carboplatin appears active in progressive childhood brain stem glioma, medulloblastoma and ependymoma. ASCO 7: A312, 1988
7. Kim TS, Halliday AL, Hedley-White ET, ConveryK: Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 74: 27-37, 1991
8. Kornblith PL, Walker M: Chemotherapy for malignant gliomas. J Neurosurg 68: 1-17, 1988
9. Müller H, Brock M, Ernst H: Long-term survival and recurrence-free interval in combined surgical, radio- and chemotherapy of malignant brain gliomas. Clin Neurol Neurosurg 87: 167-171, 1985
10. Afra D, Kocsis B, Dobay J: Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the post-operative treatment of malignant gliomas. J Neurosurg 59:106-110, 1983
11. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70: 175-182, 1989
12. Brem H,Mahaley Jr MS, Vick NA, Black KL, Schold Jr SC, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, Kenaly JN: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74: 441-446, 1991
13. Edwards MS, Levin VA, Wilson CB: Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 64: 1179-1205, 1980
14. Gutin PH, Leibel SA, Wara WM, Choucair A, Levin VA, Philips TR, Silver P, Da Silva V, Edwards MSB, Davis RL, Weaver KA, Lamb S: Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. J Neurosurg 67: 864-873, 1987
15. Leibel SA, Gutin PH, Wara WM, Silver PS, Larson DA, Edwards MSB, Lamb SA, Ham B, Weaver KA, Barnett C, Phillips TL: Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 17: 1129-1139, 1989
16. Mahaley Jr MS, Mettlin C, Natarajan N, Laws ER, Peace BB : National survey on patterns of care for brain-tumor patients. J Neurosurg 71: 826-836, 1989
17. Mahaley MS, Hipp SW, Dropcho EJ, Bertsch L, Cush S, Tirey T, Gillespie GY: Intracarotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg 70: 371-378, 1989
18. Salcman M: Survival in glioblastoma: historical perspective. Neurosurgery 7: 435-438, 1980
19. Shibamoto Y, Yamashita J, Takahashi M, Yamasaki T, Kikuchi H, Abe M: Supratentorial malignant glioma: an analysis of radiation therapy in 178 cases. Radiother Oncol 18: 9-17, 1990
20. Bianco AR, De Placido S, Gallo C, Pagliarulo C, Marinelli A, Petrella G, D'Istria M, Delrio G: Adjuvant therapy with tamoxifen in operable breast cancer: 10 year results of the Neaples (GUN) study. Lancet 2: 1095-1099, 1988
21. Corey RW, Davis JM, Zervas NT: Tamoxifen-induced regression of cerebral metastases in breast carcinoma. Cancer Treat Rep 65: 793-795, 1981
22. Hansen SB, Galsgard H, von Eyben FE, Westergaard-Nielsen V, Wolf-Jensen J: Tamoxifen for brain metastases from breast cancer. Ann Neurol 20: 544, 1986
23. Berd D, McLaughlin CJ, Hart E, Wiebe VJ, Masfrangel MJ, Beilet RE, Degregorio MW: Short course high dose tamoxifen with cytotoxic chemotherapy for metastatic melanoma. Proc ASCO 10:291, 1991
24. Couldwell WT, Antel JP, Apuzzo MLJ, Yong VW: Enhanced protein kinase-C activity determines the growth rate of malignant human gliomas. J Neurosurg 74: 368A, 1991
25. Couldwell WT, Uhm J, Antel JP, Yong VW: Enhanced protein kinase C activity correlates with the growth rate of malignant human gliomas. Neurosurgery 29: 880-887, 1991
26. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462-2465, 1985
27. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB :Triphenylethylenes: a new class of protein kinase C inhibitors. J Natl Cancer Inst 76: 1243-1246, 1986
28. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT: Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 50: 7134-7138, 1990
29. Zhang W, Yamada H, Sakai N, Niikawa S, Nozawa Y: Enhancement of radio sensitivity by tamoxifen in C6 glioma cells. Neurosurgery 31: 725-730, 1992
30. Stewart DJ, O'Bryan RM, Al-Sarraf M: Phase II study of cysplatin in recurrent astrocytomas in adults: a Southwest Oncology Group study. J Neuro-Oncol 1: 145-147, 1983
31. Vertosick FT, Selker RG, Pollack IF, Arena V: The treatment of intracranial malignant glioma using orally administered tamoxifen therapy: preliminary results in a series of 'failed' patients. Neurosurgery 30: 897-903, 1992
32. Doz F, Berens ME, Dougherty DV, Rosenblum ML: Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposure. J Neuro-Oncol 11: 27-35, 1991
33. Walker RW, Dautis E, Shapiro WR: Treatment of recurrent glioma with carboplatin (CBDCA). Proc Am Soc Clin Oncol 6: A281, 1987
34. Warnick RE, Pradof MD, Mack EE: A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neuro-Oncol 19: 69-74, 1994
35. World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication, No. 48, Geneva, 1979
36. Lunardi P, Osman Farah J, Mastronardi L, Puzzilli F, Lo Bianco FM: Intravenous administration of high-doses of carboplatin in multimodal treatment of high-grade gliomas: a phase II study. Acta Neurochir (Wien) 138: 215-220, 1996
37. Legha SS: Tamoxifen in the treatment of breast cancer. Ann Intern Med 109: 219-228, 1988
38. Couldwell WT, Antel JP, Yong VW: Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas: part II. Effects of glioma mitogens and modulators of PKC. Neurosurgery 31: 717-724, 1992
39. Horgan K, Cooke E, Hallett MB, Mansel RE: Inhibition of protein kinase-C mediated signal transduction by tamoxifen. Biochem Pharmacol 35: 4463-4465, 1986
40. Yong VW: Proliferation of human and mouse astrocytes in vitro: signalling through the PKC pathway. J Neurol Sci 111: 92-103, 1992
41. Bhat NR: Role of protein kinase C in glial cell proliferation. J Neurosci Res 22: 20-27, 1989
42. Baltuch G, Couldwell WT, Villemure JG, Yong VW: Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery 33: 495-501, 1993
43. Couldwell WT, Gopalakrishna R, Hinton DR, He S, Weiss MH, Apuzzo MIJ, Law RE: Hypericin. A potential antiglioma therapy. Neurosurgery 35: 705-710, 1994
44. Zhang W, Hinton DR, Surnock AA, Couldwell WT: Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report. Neurosurgery 38: 587-591, 1996
45. Baltuch G, Shenouda G, Langleben A, Villemure JG: High-dose tamoxifen in the treatment of recurrent high-grade glioma: a report of clinical stabilization and tumor regression. Can J Neurol Sci 20:168-170, 1993
46. Couldwell WT, Weiss MH, DeGiorgio CM, Weiner LP, Hinton DR, Ehresmann GR, Conti PS, Apuzzo MJ: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32: 485-490, 1993
47. Gewirtz RJ, Barnett GH, Cohen BH, Lupica KM: Response to tamoxifen in patients failing conventional therapy for malignant glioma. Abstract Book of the 62nd Annual Meeting of AANS, San Diego, April 9-14, p. 525, 1994
48. Langleben A, Preul M, Tampieri D et al.: Combined hormonal and chemotherapy treatment of recurrent high grade astrocytoma (Meeting abstract). Proc Ann Meet Am Ass Cancer Res 35: A1348, 1994
49. Shenouda G, Preul M, Langleben A et al.: Phase I/II trial of high-dose of tamoxifen in patients with recurrent high-grade cerebral astrocytomas: the McGill University experience (Meeting abstract). Proc Ann Meet Am Soc Clin Oncol 13: A489, 1994
50. Vertosick FT, Selker RG, Arena V: A dose-escalation study of tamoxifen therapy in patients with recurrent glioblastoma multiforme. Abstract Book of the 62nd Annual Meeting of AANS, San Diego, April 9-14, p. 116, 1994
51. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Masri L, Law RE, Apuzzo MLJ, Weiss MH: Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 2: 619-622, 1996
52. Davis C, Shaw I: Study of mega dose tamoxifen and recurrent malignant glioma (Meeting abstract). Br J Neurosurg 10: 115-116, 1996
53. Freeman A, Hetherington M, Egelhoff J et al.: Preliminary results: diffuse intrinsic brain stem gliomas of childhood respond to tamoxifen (Meeting abstract). Proc Ann Meet Am Ass Cancer Res 35: A2806, 1994
54. Endicott JA, Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 58:137-174, 1989
55. McClay EF, Albright KB, Jones JA, Christen RD, Howell SB: Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int J Cancer 55:1018-1022, 1993
56. McClay EF, Albright KB, Jones JA, Eastman A, Christen RD, Howell SB: Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res 52: 6790-6796, 1992
57. McClay EF, Albright KB, Jones JA, Christen RD, Howell SB: Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53: 1571-1576, 1993